NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor’s Eczema Treatment on Two QVC® Shows on February 7
February 06 2023 - 6:50AM
Business Wire
Calm Cool + Corrected Eczema + Dermatitis
Clinical Repair Balm to be Featured on “It Takes Two with Mary
& Sandra” at 2 p.m. ET and “Girl’s Night In With Courtney &
Jane” at 9 p.m. ET
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
that Chief Product Officer Audrey Kunin, MD will be a live on-air
guest on two QVC network shows on February 7, 2023. Dr. Kunin will
be discussing DERMAdoctor®’s problem-solving Calm Cool + Corrected
1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on
“It Takes Two With Mary & Sandra” at 2 p.m. Eastern time and on
“Girl’s Night In With Courtney & Jane” at 9 p.m. Eastern
time.
“This is the ideal time of year for our moisturizing Calm Cool +
Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair
Balm as eczema flare-ups occur more frequently in the winter months
due to cold weather and dry air from indoor heating systems,” said
Dr. Kunin. “Our clinical-strength, high-potency balm helps to
temporarily relieve eczema, rashes, redness, dryness and itchiness
and is suitable for the whole family wherever eczema strikes. Our
product packaging proudly features the National Eczema Association
Seal of Acceptance™ for meeting the Association’s rigorous standard
for providing benefits and improving the quality of life for people
with eczema and sensitive skin.
“It’s exciting to appear on these two popular QVC shows to
spotlight the significant benefits of Calm Cool + Corrected Eczema
Clinical Repair Balm,” added Dr. Kunin. “QVC attracts a demographic
that complements our social media promotions to reach the estimated
31 million Americans with eczema who may benefit from our
product.”
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis
Clinical Repair Balm features eczema-active 1% colloidal oatmeal
with enhanced beta glucan to help relieve minor skin irritations
and itching, together with an advanced complex of ceramides and
essential lipids to maximize hydration and dermatologic botanicals
that calm and soothe the skin.
Dr. Kunin is a board-certified dermatologist, author, clinician,
educator, television personality and recognized trailblazer in the
skincare industry. She founded DERMAdoctor to formulate and
commercialize highly effective, prestige solutions for common
skincare concerns that have been overlooked by the beauty industry.
DERMAdoctor delivers on the promise that clinical skin therapy can
be simple and easy to use, while providing significant and
measurable results. DERMAdoctor products are developed to provide
real solutions for real people with real skin-related concerns.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 OTC
dermatologist-developed skincare products through the DERMAdoctor
website, well-known traditional and digital beauty retailers, and
international distributors. NovaBay also manufactures and sells
effective, yet gentle and non-irritating wound care products. The
PhaseOne® brand is distributed through commercial partners in the
U.S. for professional use only, and the NeutroPhase® brand is
distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230206005067/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024